Plazomicin - Achaogen

Drug Profile

Plazomicin - Achaogen

Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Achaogen
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bacteraemia; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Preclinical Gram-negative infections
  • No development reported Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 02 Jan 2018 Planned Prescription Drug User Fee Act (PDUFA) date for Urinary tract infections (Combination therapy, Treatment-resistant) in USA (IV) is 2018-06-25
  • 02 Jan 2018 The US FDA accepts NDA for plazomicin for Urinary tract infections (Combination therapy, Treatment-resistant) for review (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top